Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Thalidomide was administered to 83 patients with myelodysplastic syndrome (MDS), starting at 100 mg by mouth daily and increasing to 400 mg as tolerated. Thirty-two patients stopped therapy before 12 weeks (minimum period for response evaluation), and 51 completed 12 weeks of therapy. International Working Group response criteria for MDS were used to evaluate responses. Intent-to-treat (ITT) analysis classified all off-study patients as nonresponders. Off-study patients belonged to a higher risk category (P = .002) and had a higher percentage of blasts in their pretherapy bone marrow than patients who completed 12 weeks of therapy (P = .003). No cytogenetic or complete responses were seen, but 16 patients showed hematologic improvement, with 10 previously transfusion-dependent patients becoming transfusion independent. Responders had lower pretherapy blasts (P = .016), a lower duration of pretherapy platelet transfusions (P = .013), and higher pretherapy platelets (P = .003). Among responders, 9 had refractory anemia (RA); 5 had RA with ringed sideroblasts; and 2 had RA with excess blasts. By ITT analysis, 19% of patients (16 of 83) responded, and when only evaluable patients were analyzed, 31% (16 of 51) responded. It was concluded that thalidomide, as a single agent, is effective in improving cytopenias of some MDS patients, especially those who present without excess blasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationThalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Cheson, B. D., Bennett, J. M., Kantarjian, H. M., Pinto, A., Schiffer, C. A., Nimer, S. D., Löwenberg, B., Beran, M., de Witte, T. M., Stone, R. M., et al. (2000) · PubMed · Cited by 666
Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization
KENYON, B. M., BROWNE, F., & D'AMATO, R. J. (1997) · Experimental Eye Research · doi:10.1006/exer.1997.0292 · Cited by 440
Raza, A., Gezer, S., Mundle, S., Gao, X., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V, & Parcharidou, A. (1995) · Blood · doi:10.1182/blood.v86.1.268.bloodjournal861268 · Cited by 424
Self-citationBellamy, W. T., Richter, L., Sirjani, D., Roxas, C., Glinsmann-Gibson, B., Frutiger, Y., Grogan, T. M., & List, A. F. (2001) · Blood · doi:10.1182/blood.v97.5.1427 · Cited by 342
Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., et al. (1998) · Blood · doi:10.1182/blood.v92.1.68.413k23_68_75 · Cited by 304
Activity of Thalidomide in AIDS-Related Kaposi’s Sarcoma
Little, R. F., Wyvill, K. M., Pluda, J. M., Welles, L., Marshall, V., Figg, W. D., Newcomb, F. M., Tosato, G., Feigal, E., Steinberg, S. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2593 · Cited by 290
Angiogenesis in myelodysplastic syndromes
Pruneri, G., Bertolini, F., Soligo, D., Carboni, N., Cortelezzi, A., Ferrucci, P. F., Buffa, R., Lambertenghi-Deliliers, G., & Pezzella, F. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6693515 · Cited by 271
Mchugh, S. M., Rifkin, I. R., Deighton, J., Wilson, A. B., Lachmann, P. J., Lockwood, C. M., & Ewan, P. W. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb05527.x · Cited by 263
Kitagawa, M., Saito, I., Kuwata, T., Yoshida, S., Yamaguchi, S., Takahashi, M., Tanizawa, T., Kamiyama, R., & Hirokawa, K. (1997) · Leukemia · doi:10.1038/sj.leu.2400844 · Cited by 254
Deeg, H. J., Shulman, H. M., Anderson, J. E., Bryant, E. M., Gooley, T. A., Slattery, J. T., Anasetti, C., Fefer, A., Storb, R., & Appelbaum, F. R. (2000) · Blood · doi:10.1182/blood.v95.4.1188.004k38_1188_1194 · Cited by 190
Shetty, V., Mundle, S., Alvi, S., Showel, M., Broady-Robinson, L., Dar, S., Borok, R., Showel, J., Gregory, S., Rifkin, S., et al. (1996) · Leukemia Research · doi:10.1016/s0145-2126(96)00008-2 · Cited by 177
Self-citationyndromes, I. T. C. O. S. T. G. R. R. I. M. Y. S. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01085.x · Cited by 174
Molldrem, J. J., Jiang, Y. Z., Stetler‐Stevenson, M., Mavroudis, D., Hensel, N., & Barrett, A. J. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00920.x · Cited by 160
Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes
Bouscary, D., De Vos, J., Guesnu, M., Jondeau, K., Viguier, F., Melle, J., Picard, F., Dreyfus, F., & Fontenay-Roupie, M. (1997) · Leukemia · doi:10.1038/sj.leu.2400654 · Cited by 159
Raza (1996) · International Journal of Hematology · doi:10.1016/0925-5710(96)00455-0 · Cited by 141
Thalidomide as an Anti-TNF-α Inhibitor: Implications for Clinical Use
Klausner, J. D., Freedman, V. H., & Kaplan, G. (1996) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1996.0181 · Cited by 140
Immunosuppressive therapy for hypoplastic myelodysplastic syndrome
Biesma, D. H., van den Tweel, J. G., & Verdonck, L. F. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970415)79:8<1548::aid-cncr16>3.0.co;2-y · Cited by 138
Beran, M., Estey, E. H., O'Brien, S. M., Cortes, J. E., Koller, C. A., Giles, F. J., Kornblau, S. M., Andreeff, M., Vey, N., Pierce, S. R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2819 · Cited by 136
Stimulation of Hematopoiesis by Amifostine in Patients With Myelodysplastic Syndrome
List, A. F., Brasfield, F., Heaton, R., Glinsmann‐Gibson, B., Crook, L., Taetle, R., & Capizzi, R. L. (1997) · Blood · doi:10.1182/blood.v90.9.3364 · Cited by 123
Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages
Tavares, J. L., Wangoo, A., Dilworth, P., Marshall, B. G., Kotecha, S., & Shaw, R. J. (1997) · Respiratory Medicine · doi:10.1016/s0954-6111(97)90134-7 · Cited by 107
Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes
Raza, A. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000801)50:3<229::aid-jemt6>3.0.co;2-h · Cited by 101
Self-citationThompson, J. A., Gilliland, D. G., Prchal, J. T., Bennett, J. M., Larholt, K. M., Nelson, R. A., Rose, E. H., Dugan, M. H., & the GM/EPO MDS Study Group (2000) · Blood · doi:10.1182/blood.v95.4.1175.004k51_1175_1179 · Cited by 95
Mundle, S. D., Venugopal, P., Cartlidge, J., Pandav, D., Broady-Robinson, L., Gezer, S., Robin, E., Rifkin, S., Klein, M., Alston, D., et al. (1996) · Blood · doi:10.1182/blood.v88.7.2640.bloodjournal8872640 · Cited by 86
Self-citationRaza, A., Qawi, H., Lisak, L., Andric, T., Dar, S., Andrews, C., Venugopal, P., Gezer, S., Gregory, S. A., Loew, J. M., et al. (2000) · Blood · doi:10.1182/blood.v95.5.1580.005k45_1580_1587 · Cited by 72
Self-citationBogdanovic, A. D., Trpinac, D., Janković, G., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400640 · Cited by 63
A patient-oriented approach to treatment of myelodysplastic syndromes.
Cazzola, M., Anderson, J. E., Ganser, A., & Hellström‐Lindberg, E. (1998) · PubMed · Cited by 56
Ching, L., Browne, W., Tchernegovski, R., Gregory, T., Baguley, B., & Bd, P. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.495 · Cited by 46
Allampallam, K., Shetty, V., Hussaini, S., Mazzoran, L., Zorat, F., Huang, R., & Raza, A. (1999) · PubMed · Cited by 37
Self-citationAcute leukemias VII : experimental approaches and novel therapies
Hiddemann, W. (1998) · Springer eBooks · Cited by 36
Combined differentiating therapy for myelodysplastic syndromes: A phase II study
Ferrero, D., Bruno, B., Pregno, P., et al. (1996) · Leukemia Research · doi:10.1016/0145-2126(95)00156-5 · Cited by 35
Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes
Cheson, B. D. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00039-3 · Cited by 31
DIFFERENTIATION THERAPY OF MYELODYSPLASTIC SYNDROMES: FACT OR FICTION?
Santini, V., & Ferrini, P. R. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00881.x · Cited by 28
Apoptotic megakaryocyte dysplasia in the myelodysplastic syndromes.
Hatfill, S. J., Fester, E., & Jg, S. (1992) · PubMed · Cited by 25
All-Trans Retionic ACid in the Treatment of Myelodysplastic Syndromes
Visani, G., Tosi, P., Manfroi, S., Ottaviani, E., Finelli, C., Cenacchi, A., Bendandi, M., Tura, S., Imamura, M., Kasai, M., et al. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509107898 · Cited by 24
Pham-Huy, C., Galons, H., Voisin, J., et al. (1997) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(97)00067-2 · Cited by 16
Treatment of Myelodysplastic Syndromes
Komrokji, R. S. (2023) · Wiley eBooks · doi:10.1002/9781119823193.ch13 · Cited by 10
Cited by
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Self-citationMalcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
Franks, M. E., Macpherson, G. R., & Figg, W. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16308-3 · Cited by 615
Raza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, H. J., Dreisbach, L., Schiffer, C. A., Stone, R. M., Greenberg, P. L., et al. (2008) · Blood · doi:10.1182/blood-2007-01-068833 · Cited by 425
Self-citation
Metadata
- Authors
- Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C., Goldberg, C., Loew, J., Dar, S., Gezer, S., Venugopal, P., & Zeldis, J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-08-15
- Volume
- 98
- Issue
- 4
- Pages
- 958-965
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2117327010
- Cited by
- 305
- References
- 42
- FWCI
- 12.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.